Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

ZEALAND PHARMA AS

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: -

Established: 1998-01-01

Employees: 150

Market Cap: $9.1B

Website: https://www.zealandpharma.com/

Clinical Trials

Evaluation of the Safety, Tolerability and Bioavailability of Dasiglucagon Following Subcutaneous (SC) Compared to IV Administration

Phase 1

Completed

Conditions: Hypoglycemia

Interventions: Drug: Placebo
Drug: Dasiglucagon

First Posted Date: 2018-11-08

Last Posted Date: 2021-03-23

Lead Sponsor: Zealand Pharma

Target Recruit Count: 60

Registration Number: NCT03735225

Locations: 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany

Efficacy And Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome (SBS)

Phase 3

Completed

Conditions: Short Bowel Syndrome

Interventions: Drug: glepaglutide
Drug: Placebo

First Posted Date: 2018-10-01

Last Posted Date: 2024-10-21

Lead Sponsor: Zealand Pharma

Target Recruit Count: 106

Registration Number: NCT03690206

Locations: 🇺🇸
Georgetown University Medical Center, Washington, District of Columbia, United States
🇺🇸
University of Chicago Children's Hospital, Chicago, Illinois, United States
🇺🇸
Mayo Clinic College of Medicine, Rochester, Minnesota, United States

and more 26 locations

Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Subjects With T1DM

Phase 3

Completed

Conditions: Hypoglycemia
Diabetes Mellitus, Type 1

Interventions: Drug: Placebo
Drug: Dasiglucagon

First Posted Date: 2018-09-28

Last Posted Date: 2021-05-19

Lead Sponsor: Zealand Pharma

Target Recruit Count: 45

Registration Number: NCT03688711

Locations: 🇺🇸
ProSciento, Inc., Chula Vista, California, United States
🇺🇸
AMCR Institute, Escondido, California, United States
🇺🇸
Rainier Clinical Research, Inc., Renton, Washington, United States

Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in T1DM Children

Phase 3

Completed

Conditions: Hypoglycemia

Interventions: Drug: GlucaGen HypoKit
Drug: placebo
Drug: dasiglucagon

First Posted Date: 2018-09-12

Last Posted Date: 2021-06-30

Lead Sponsor: Zealand Pharma

Target Recruit Count: 42

Registration Number: NCT03667053

Locations: 🇺🇸
AMCR Institute, Inc, Escondido, California, United States
🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States
🇺🇸
Indiana University, Department of Pediatrics, Indianapolis, Indiana, United States

and more 2 locations

A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes Subjects

Phase 3

Completed

Conditions: Hypoglycemia
Diabetes Mellitus, Type 1

Interventions: Drug: Dasiglucagon
Drug: Placebo
Drug: GlucaGen

First Posted Date: 2017-12-20

Last Posted Date: 2021-06-10

Lead Sponsor: Zealand Pharma

Target Recruit Count: 170

Registration Number: NCT03378635

Locations: 🇺🇸
ProSciento, Chula Vista, California, United States
🇦🇹
Clinical Research Center, Medizinische Universität Graz, Graz, Austria
🇨🇦
LMC Diabetes & Manna Research, Toronto, Canada

and more 1 locations

Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: Glepaglutide

First Posted Date: 2017-09-12

Last Posted Date: 2017-12-22

Lead Sponsor: Zealand Pharma

Target Recruit Count: 75

Registration Number: NCT03279302

Locations: 🇺🇸
Covance CRU, Dallas, Texas, United States

A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes Mellitus

Phase 3

Completed

Conditions: Hypoglycemia
Diabetes Mellitus, Type 1

Interventions: Drug: dasiglucagon
Drug: GlucaGen

First Posted Date: 2017-07-13

Last Posted Date: 2021-05-04

Lead Sponsor: Zealand Pharma

Target Recruit Count: 112

Registration Number: NCT03216226

Locations: 🇺🇸
Compass Research, Orlando, Florida, United States
🇺🇸
Advanced Clinical Research, Meridian, Idaho, United States
🇦🇹
CRC - Clinical Research Center, Medizinische Universität Graz, Graz, Austria

and more 4 locations

Feasibility Trial Testing the Bionic Pancreas With ZP4207

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 1

Interventions: Drug: Insulin Lispro
Drug: ZP4207 (dasiglucagon)
Drug: Glucagon
Device: iPhone-based bionic pancreas
Device: iLet-based bionic pancreas

First Posted Date: 2016-11-22

Last Posted Date: 2021-03-23

Lead Sponsor: Zealand Pharma

Target Recruit Count: 13

Registration Number: NCT02971228

Locations: 🇺🇸
MGH Diabetes Center, Boston, Massachusetts, United States

ZP4207(Dasiglucagon) Administered to T1D Patients to Assess the PK and PD Compared to Marketed Glucagon

Phase 2

Completed

Conditions: Diabetes Mellitus Type 1

Interventions: Drug: ZP4207(dasiglucagon) glucagon analogue
Drug: Glucagon (Native glucagon)

First Posted Date: 2016-09-27

Last Posted Date: 2017-04-21

Lead Sponsor: Zealand Pharma

Target Recruit Count: 38

Registration Number: NCT02916251

Locations: 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, North Rhine-Westphalia, Germany

A Phase 2 Trial Testing ZP1848 in Patients With SBS

Phase 2

Completed

Conditions: Short Bowel Syndrome

Interventions: Drug: ZP1848

First Posted Date: 2016-02-24

Last Posted Date: 2017-06-21

Lead Sponsor: Zealand Pharma

Target Recruit Count: 18

Registration Number: NCT02690025

Locations: 🇩🇰
Rigshospitalet, Copenhagen, Denmark

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy